NEW YORK--(BUSINESS WIRE)--BioPontis Alliance, LLC announced today that it has entered into an innovative strategic agreement with Merck (known outside the US and Canada as MSD) designed to bridge the gap between early academic discovery science and the development of medicines and technologies that impact human health. The announcement was made this week at the prestigious Partnering For Cures Conference that is convened annually for the purpose of forging strategic cross-sector collaborations.
